#United States #San Francisco #NKTR #Nektar_Therapeutics #stock_options

Nektar Therapeutics Stock Option Grant Announcement

On September 25, 2026, Nektar Therapeutics (NASDAQ: NKTR), a leading biotechnology firm, disclosed significant stock options granted to eleven new hires. This action was taken by the Organization and Compensation Committee of the Board of Directors on September 18, 2026. The company issued a total of 58,600 stock options and 2,450 Restricted Stock Units (RSUs) as part of their 2025 Inducement Plan, which was specifically designed to attract and secure talent who are not previously associated with Nektar.

The 2025 Inducement Plan, adopted on November 6, 2025, adheres to Nasdaq Listing Rule 5635(c)(4) which allows companies to provide equity awards to new employees as an employment incentive. This strategic move aims to encourage worthwhile talent to join Nektar, thereby enhancing the company's capability and innovative potential in the biotech industry.

Details of the Stock Options and RSUs

The stock options granted come with an exercise price of $67.10 per share, reflecting the closing stock price on the date of the grant. These stock options are set to vest over a four-year period. Specifically, 25% of the shares will become available on the first anniversary of the grant date, and the remaining will vest in 1/48th increments on a monthly basis during the following three years, contingent on the employees’ continued employment.

For the Restricted Stock Units (RSUs), similar vesting conditions apply. The RSUs will also vest over a period of four years, with 25% vesting on the first anniversary followed by quarterly vesting of 1/16th of the shares in the subsequent years. Both the RSUs and stock options are governed by the terms outlined in Nektar's 2025 Inducement Plan along with related agreements.

About Nektar Therapeutics

Nektar Therapeutics operates at the forefront of biomedical research, focusing on groundbreaking treatments for various autoimmune diseases and chronic inflammatory conditions. The company’s flagship candidate, rezpegaldesleukin (known as REZPEG or NKTR-358), is currently undergoing trials for its effectiveness in treating atopic dermatitis, alopecia areata and Type 1 diabetes. Nektar's portfolio also includes several promising investigational agents such as NKTR-0165 and NKTR-0166, designed to tackle different aspects of immune response.

With a commitment to innovative healthcare solutions, Nektar is headquartered in San Francisco, California, and continues to expand its pipeline of potential therapies aimed at addressing unmet medical needs. For more comprehensive information about Nektar Therapeutics, interested parties are encouraged to visit their official website at www.nektar.com or follow the company on LinkedIn.

Conclusion

This recent announcement by Nektar Therapeutics shines a light on the company's commitment to recruiting and nurturing talent as it enhances its research and development landscape. By providing strategic stock option grants under the 2025 Inducement Plan, Nektar not only incentivizes new hires but aims to unify their commitment towards its mission of delivering innovative therapeutics to improve patient lives globally.

Through its ongoing research, Nektar is well-positioned to make significant strides in the biotechnology sector, crafting a brighter future for treating complex health conditions. As stakeholders look forward to future developments, this step reflects Nektar’s resolve to remain competitive and dedicated in the ever-evolving medical landscape.